Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...

The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

Several users of the Trust Wallet Chrome extension report having their cryptocurrency wallets drained after installing a ...

BHVN’s investment case definitely weakened after Opakalim’s Phase 2 MDD miss. This also means they’ll discontinue their ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

Investing.com -- AstraZeneca PLC (ST:AZN) announced Monday that its LATIFY Phase III trial of ceralasertib in combination ...

Although there are several effective anti-osteoporosis drugs on the market today, new therapies with improved safety profiles and efficacy are still needed. The FDA called osteoporosis-related ...

The adoption of the FAIR model was pivotal in transforming our cybersecurity strategy into a measurable, business-aligned ...